Aarti Drugs posts Q2 FY25 consolidated profit at Rs. 35.01 Cr

Aarti Drugs has reported total income of Rs. 599.81 crores during the period ended September 30, 2024

Akums Drugs enters into license and distribution agreement with Triple Hair, Canada

Akums Drugs will undertake this development and commercialization in India

Venus Remedies secures marketing authorisations for key oncology drugs from Morocco

The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia

Briefs: Biocon, Aarti Drugs and Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations

Combination of ‘Siddha’ drugs reduces anemia in adolescent girls: Study

The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme

Mangalam Drugs & Organics awarded US$ 274,800 grant by MMV

The grant is designated for the research and development of Pyronaridine

Mangalam Drugs & Organics expanding anti-malaria APl portfolio with introduction of Pyronaridine

This development will position the company at the forefront of anti- malaria API production globally and is expected to drive substantial growth and profitability

Aarti Drugs posts Q1 FY25 PAT lower at Rs. 33.3 Cr

PharmaLytica 2024: India exported US$ 27.8 billion worth of drugs in FY 2023-24

The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030

Aarti Drugs posts Q4 FY24 consolidated PAT at Rs. 47.37 Cr

The company has posted net profit of Rs.171.42 crores for the Financial Year ended March 31, 2024